Organon & Co. reported a 3% revenue decline in 2025 due to Atozet’s loss of exclusivity and respiratory franchise challenges. Biosimilars performed well, with 61% growth for Hadlima. Operational efficiency saved $200 million, offsetting margin degradation. The company divested Jada for $390 million to focus on existing products and growth drivers like Vtama.

2026 guidance predicts flat revenue and EBITDA at $6.2 billion and $1.9 billion. Nexplanon’s FDA approval for a 5-year duration aims to expand the market. Management focuses on leveraging global assets like Emgality and Nilemdo. Manufacturing separation costs are estimated at $100 million in 2026.

A noncash goodwill impairment of $301 million was recorded, reflecting stock price decline. The OECD Pillar 2 global minimum tax may raise the non-GAAP tax rate to 27.5% – 29.5% in 2026. A new REMS program for Nexplanon requires prescriber recertification. The company aims to reduce net leverage below 4x by the end of 2026.

Read more at Yahoo Finance: Organon & Co. Q4 2025 Earnings Call Summary